CD8A and infectious disease: In this proof-of-concept study, HR2-DoriVac, conjugated with infectious-disease-associated peptides and proteins, elicited robust neutralizing antibodies and antigen-specific CD4 and CD8 T cell activation in healthy mice, a notable contrast to some SARS-CoV-2 vaccines with limited T cell responses.